Jilin Xidian Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as "the Company") announces that its holding subsidiary, Jilin Shuangshengfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Subsidiary"), has recently received the Vitamin B12 injection "Drug Registration Certificate" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant information is announced as follows:
301130SZSE
Announcement on Subsidiary's Vitamin B12 Injection Obtaining Drug Registration Certificate
✨ AI Summary
Jilin Xidian Pharmaceutical Technology Development Co., Ltd. announced that its subsidiary, Jilin Shuangshengfeng Pharmaceutical Co., Ltd., has received a drug registration certificate for Vitamin B12 injection from the National Medical Products Administration. This approval enhances the company's product line and market competitiveness. However, the company warns of potential uncertainties in sales due to industry policy changes and market conditions.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.